| Jul 25, 2024 | Imperative Care | $150.0M Series E | Frank Yu | AMED Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, HealthCor Family Office, Innovatus Capital Partners, INTAI Technology, Montreux Equity Partners, Rock Springs Capital |
| Feb 15, 2024 | Freenome | $254.0M Other Equity | Matt Sause | American Cancer Society, Andreessen Horowitz, ARK Invest, ArrowMark Partners, Bain Capital Life Sciences, Data Collective, Eventide Asset Management, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Mark A. Gardner, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates |
| Jan 10, 2023 | Monogram Health | $375.0M Other Equity | Cigna Ventures, CVS Health Ventures, Bill Frist, Heritage Group, Humana, Memorial Hermann Health System, Norwest Venture Partners, Pura Vida Investments, SCAN Group, Kendall Garrison | — |
| Feb 18, 2022 | Nalu Medical | $104.0M Other Equity | Hugo Harrod | Advent Life Sciences, Aperture Venture Partners, Decheng Capital, Endeavour Vision, Longitude Capital |
| Jan 1, 2022 | Metagenomi | $180.0M Series B | Farallon Capital Management, Santhosh Palani, PhD, CFA | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Humboldt Fund, Nextech Invest, OrbiMed, RA Capital, Tencent Holdings, Jeremy Yap, Bristol Myers Squibb, Deep Track Capital, Eventide Asset Management, Frazier Life Sciences, Irving Investors, Leaps by Bayer, Marshall Wace, Millennium Management, Moderna, Novo Holdings, RA Capital Management, Surveyor Capital |
| Dec 1, 2021 | NanoMosaic | $41.0M Series A | RA Capital Management | RA Capital, Insight Partners, John Boyce, Time BioVentures |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Data Collective, Eventide Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Google Ventures, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Ridgeback Capital Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Dec 1, 2021 | V-Wave | $98.0M Wave - Series C | Deerfield Management | Aperture Venture Partners, BRM Group, Endeavour Vision, GHS Fund, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax, Triventures |
| Jul 1, 2021 | Exo | $220.0M Series C | Zach Scheiner | RA Capital, Avidity Partners, BlackRock, Sands Capital |
| Apr 23, 2021 | Willow | $26.8M Series C Extension | Endeavour Vision | Gaingels, Logos Capital, NEA, Purple Arch Ventures |
| Apr 16, 2021 | LUMICKS | $93.0M Series D | Farallon Capital Management, Alex Slack | Irving Investors, Parian Global, SoftBank Vision Fund 2, T. Rowe Price Associates |
| Apr 1, 2021 | Ultivue | $50.0M Series D | — | ARCH Venture Partners, Kilonova Capital, Northpond Ventures, Razor's Edge Ventures, Anna Yaeger, Applied Ventures, Tao Capital Partners |
| Apr 1, 2021 | Vizgen | $37.0M Series B | Northpond Ventures, Marijn Dekkers | Ascension Ventures, GE Ventures, Innovation Endeavors, Lightbank, Social Capital, Bill Gates, David R. Walt, ARCH Venture Partners, Tao Capital Partners |
| Mar 4, 2021 | atai Life Sciences | $157.0M Series D | Christian Angermayer, Apeiron Investment Group, Thiel Capital | Catalio Capital Management, Falcon Edge Capital, Fearless Ventures, Highline Capital Management, Michael Auerbach, Woodline Partners |
| Jan 1, 2021 | Sensei Biotherapeutics | $30.0M Series B | Christian Angermayer, George Petrocheilos | Catalio Capital, Helium-3 Ventures, Inveready Technology Investment Group, MMC Ventures, Platanus Ventures, Presight Capital, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn, Cambrian Biopharma, Steve Jurvetson |
| Nov 18, 2020 | MedAvail | $84.0M Other Equity | Frank Yu | Adage Capital Management, Cigna Ventures, Cowen Healthcare Investments, Heights Capital Management, Lewis & Clark Ventures, Maven Investment Partners, Redmile Group |
| Oct 1, 2020 | atai Life Sciences | $30.0M Series C | Christian Angermayer, Jacob Vogelstein | Endeavor8, Endeavor Venture Funds, Northpond Ventures, Wilbur-Ellis [Cavallo], Falcon Edge Capital, Future Ventures, Galaxy Digital, Peter Thiel |
| Jun 20, 2019 | Acutus Medical | $170.0M Debt / Series D | — | Vince Burgess, Advent Venture Partners, Deerfield Management, GE Ventures, Opaleye Management, OrbiMed, Xeraya Capital |
| Jul 25, 2018 | MedAvail | $16.6M Other Equity | Glen Stettin, Helen Ciesielski | Adage Capital Management, Deerfield Management, Dave Rawlins |
| Apr 1, 2018 | V-Wave | $70.0M Wave - Series C | Deerfield Management | Aperture Venture Partners, BioStar Ventures, BRM Group, Edwards Lifesciences, Endeavour Vision, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax, Quark Venture, Triventures |
| Jan 11, 2016 | V-Wave | $28.0M Wave - Series B | — | BioStar Ventures, BRM Group, Edwards Lifesciences, Johnson & Johnson Innovation, Pontifax, Triventures |
| Oct 17, 2014 | MedAvail | $30.0M Series C | Frank Litvack | Adage Capital Management, Deerfield Management, Redmile Group, Walgreens, Walgreens Boots Alliance |
